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Abstract
Background: Lack of suitable mouse models has hindered the studying of diabetic macrovascular complications.
We examined the effects of type 2 diabetes on coronary artery disease and cardiac function in
hypercholesterolemic low-density lipoprotein receptor-deficient apolipoprotein B100-only mice (LDLR
-/-ApoB
100/100).
Methods and results: 18-month-old LDLR
-/-ApoB
100/100 (n = 12), diabetic LDLR
-/-ApoB
100/100 mice overexpressing
insulin-like growth factor-II (IGF-II) in pancreatic beta cells (IGF-II/LDLR
-/-ApoB
100/100, n = 14) and age-matched
C57Bl/6 mice (n = 15) were studied after three months of high-fat Western diet. Compared to LDLR
-/-ApoB
100/100
mice, diabetic IGF-II/LDLR
-/-ApoB
100/100 mice demonstrated more calcified atherosclerotic lesions in aorta. However,
compensatory vascular enlargement was similar in both diabetic and non-diabetic mice with equal atherosclerosis
(cross-sectional lesion area ~60%) and consequently the lumen area was preserved. In coronary arteries, both
hypercholesterolemic models showed significant stenosis (~80%) despite positive remodeling. Echocardiography
revealed severe left ventricular systolic dysfunction and anteroapical akinesia in both LDLR
-/-ApoB
100/100 and IGF-II/
LDLR
-/-ApoB
100/100 mice. Myocardial scarring was not detected, cardiac reserve after dobutamine challenge was
preserved and ultrasructural changes revealed ischemic yet viable myocardium, which together with coronary
artery stenosis and slightly impaired myocardial perfusion suggest myocardial hibernation resulting from chronic
hypoperfusion.
Conclusions: LDLR
-/-ApoB
100/100 mice develop significant coronary atherosclerosis, severe left ventricular
dysfunction with preserved but diminished cardiac reserve and signs of chronic myocardial hibernation. However,
the cardiac outcome is not worsened by type 2 diabetes, despite more advanced aortic atherosclerosis in diabetic
animals.
Background
Type 2 diabetes is associated with a marked increase in
t h er i s ko fc o r o n a r yh e a r td i s e a s e[ 1 , 2 ] .S t i l l ,t h e
mechanisms underlying macrovascular diseases in type 2
diabetic patients remain unclear. In recent years various
models combining disorders of lipid and glucose meta-
bolism have been generated and they have provided
valuable information. However, better and more appro-
priate models are urgently needed.
To date, development of mouse models describing
diabetic macrovascular disease has been limited. The
effect of hyperglycemia has been widely studied in ather-
osclerotic models by streptozotosin-induced beta cell
destruction [3]. However, while hyperglycemia is an
important factor in microvascular complications of dia-
betes, its role in macrovascular events is less dominant
[4] and animal studies have not been consistent [5-8].
Thus, achieving models representing the overall meta-
bolic changes typical for diabetic patients with the
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been pursued by cross-breeding leptin-deficient (ob/ob)
or leptin receptor-deficient (db/db) mice with athero-
sclerotic ApoE
-/- [9-11] and LDLR
-/- [9,12] mice. Recently
the ob/ob mouse was cross-bred also with ApoE
-/-
ApoB
100/100 and LDLR
-/-ApoB
100/100 mice [13], resulting
in promising models of metabolic syndrome. However, a
major shortcoming in these models is that the perturba-
tion of glucose metabolism does not appear to affect
atherosclerosis without concomitant elevations in plasma
lipid levels [14,15]. Also data about their cardiac pheno-
type is scarce - there are only a few studies on ventricular
function of ob/ob/LDLR
-/- mice [16-18], although differ-
entiating the effects of diabetes from those of hypercho-
lesterolemia cannot be done without comparisons to
non-diabetic hypercholesterolemic mice. In addition, the
status of coronary artery atherosclerosis and its relation
to cardiac function have not been studied in any compar-
able models of diabetic macrovascular disease.
We have previously developed a mouse model of dia-
betic macroangiopathy, where mice overexpressing IGF-
II in pancreatic beta cells [19] in hypercholesterolemic
LDLR
-/-ApoB
100/100 background represent hyperglyce-
mia, insulin resistance and mild hyperinsulinemia with-
out concomitant changes in plasma lipid levels [20]. To
study the cardiac phenotype of hypercholesterolemic
LDLR
-/-ApoB
100/100 mice and to see if it is impaired by
diabetes, we now evaluated the extent of coronary artery
disease (CAD) and its effects on myocardial perfusion,
left ventricular function and cardiac reserve in vivo.
Senescent animals were used to simulate the respective
human patient population, and C57Bl/6 mice were
included to control the effects of aging and high fat diet.
Methods
Animals
We have previously developed IGF-II/LDLR
-/-ApoB
100/
100 mouse as a model of diabetic macroangiopathy [20].
In the present study, IGF-II negative LDLR
-/-ApoB
100/100
littermates served as controls and we also included
matched C57Bl/6J mice to control the effects of aging
and high-fat diet. Mice (n = 12-15/strain) were fed ad
libitum with a normal chow diet (R36, Lactamin, Swe-
d e n ) .A tt h ea g eo f1 5m o n t h sm i c ew e r ep u to nah i g h
fat Western diet (TD 88173, Harlan Teklad: 42% of cal-
ories from fat and 0.15% from cholesterol) for three
months, thus the animals were 18 months old at the
time of analysis. Both female and male mice were used
in this study. Experiments were approved by the
National Experimental Animal Board.
Metabolic analyses
Glucose tolerance test (GTT) and blood glucose mea-
surements were carried out in mice fasted overnight (15
h) as described [20]. Triglycerides and total cholesterol
were determined from fasting plasma samples as
described [21].
Echocardiography
Transthoracic echocardiography was performed in iso-
flurane anesthetized mice at rest and after inotropic sti-
mulation with dobutamine using a high-resolution
imaging system for small animals (Vevo 770, VisualSo-
nics Inc., Canada) equipped with a high-frequence ultra-
sound probe (RMV-707B) as described [22]. Left
ventricular (LV) dimensions and wall thicknesses were
determined from parasternal short axis M-mode images.
Ejection fraction (EF), fractional shortening (FS), LV
volume and LV mass were calculated by Vevo770 soft-
ware. EF was determined by using the Teicholz formula.
The data represent averaged values of 3 cardiac cycles.
The b-adrenoceptor agonist dobutamine (1 μg/g) was
injected intraperitoneally (n = 5-6/strain) and echocar-
diography was performed at baseline and 1, 5, 10 and 15
minutes after injection. The values of individual peak
response were used. Regional LV wall motion was evalu-
ated before and after dobutamine stress from electrocar-
diogram kilohertz-based visualization (EKV™)c i n e
loops. A 12-segment model on two levels of short axis
views (mid-ventricle and apical) comprising of 6 wall
segments (anterior, anterolateral, inferolateral, inferior,
and inferoseptal) was used. Wall motion was scored 1 =
normal, 2 = hypokinetic, 3 = akinetic and 4 = dyskinetic,
and a score index was calculated as the sum of scores
divided by the total number of segments. In addition to
the regional evaluation of the myocardium in dobuta-
mine stress echocardiography, LV wall motion was also
assessed in all animals (n = 11-13/strain) from long-axis
cine view.
Myocardial perfusion
Myocardial perfusion was quantified as described [22].
Briefly, perfusion was measured with Cadence™ con-
trast pulse sequence (CPS) ultrasound by Acuson
Sequoia C256 using 15L8 probe (Siemens Medical Solu-
tions, USA) and a second generation microbubble con-
trast agent (SonoVue, Bracco Diagnostics Inc., USA)
administered as a 50 μl bolus via tail vein. Datapro
(v2.13, Noesis SA, France) was used to quantify CPS sig-
nal intensities.
Histology
Mice were sacrificed with carbon dioxide and perfused
with phosphate-buffered saline. Tissue samples were
immersion-fixed with 4% paraformaldehyde (pH 7.4).
Aortas were embedded in paraffin after which cross-sec-
tional lesion areas from the sinus level [21] and lesion
calcification [20] were quantified as described. To
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luminal narrowing was measured as a percentage from
the area enclosed by the internal elastic lamina in serial
cross-sections [23]. Vascular remodeling ratio was calcu-
lated by dividing individual cross-sectional vessel areas
by the average area of the C57Bl/6J controls, and classi-
fied as inward (< 0.95), absent (0.95-1.05) or outward
remodeling (> 1.05) [24]. Myocardial fibrosis was quan-
tified from Masson Trichome stained serial sections
from the level of basal ventricle to apex. Analyses were
performed in a blinded fashion using AnalySIS software
(Soft Imaging System GmbH).
Electron microscopy
Tissue specimens were fixed overnight in 2.5% glutaral-
dehyde, treated with 1% osmium tetroxide, dehydrated
and embedded in LX-112 resin and polymerized. The
60-70 nm sections were contrasted with uranyl acetate
and lead citrate and examined by transmission electron
microscopy (JEM 1200EX, JEOL Ltd. Japan).
Statistical analysis
Student’s paired t-test was used for analyzing individual
response to dobutamine stress, one-way ANOVA with
Bonferroni’s post test was used for detecting differences
between the mouse strains and ANOVA of repeated
measures was applied to analyze the results of GTT. P <
0.05 was considered significant. Numerical values are
shown as mean ± standard deviation (SD). Statistical
analyses were performed using GraphPad Prism 4.0.
Results
Basic metabolic parameters
Metabolic parameters are presented in Table 1. Interest-
ingly, body weight tended to be higher in C57Bl/6J
mice, especially in males. Nevertheless, it did not reflect
on other metabolic factors such as blood glucose or glu-
cose tolerance - the IGF-II/LDLR
-/-ApoB
100/100 mice
showed both fasting hyperglycemia (8.2 ± 3.0 mmol/l)
and impaired glucose tolerance in intraperitoneal GTT
(2-hour post-glucose load 14.7 ± 6.0 mmol/l) compared
to LDLR
-/-ApoB
100/100 and C57Bl/6J mice (Table 1 Fig-
ure 1). Due to common genetic background and high
fat diet the total cholesterol levels were significantly
higher, although equal, in both LDLR
-/-ApoB
100/100 and
IGF-II/LDLR
-/-ApoB
100/100 mice (25.5 ± 7.9 and 27.8 ±
5.0 mmol/l, respectively) compared to C57Bl/6J controls
(3.9 ± 1.4 mmol/l). However, in triglycerides there was
no difference between C57Bl/6J and LDLR
-/-ApoB
100/100
mice (1.0 ± 0.3 and 1.1 ± 0.3 mmol/l, respectively),
whereas in diabetic IGF-II/LDLR
-/-ApoB
100/100 mice the
concentration was slightly elevated (1.5 ± 0.5 mmol/l, P
< 0.05).
Atherosclerosis in hypercholesterolemic mice is
accompanied by compensatory vascular remodeling and
aggravated by calcification in IGF-II/LDLR
-/-ApoB
100/100
mice
Atherosclerosis was quantified from serial aortic cross-
sections from the sinus level. No lesions were detected
in aortas of C57Bl/6J mice, whereas in LDLR
-/-ApoB
100/
100 and IGF-II/LDLR
-/-ApoB
100/100 mice lesion areas
were 61.1 ± 8.7% and 60.0 ± 7.9% of the total aortic
area, respectively (Figure 2A, D). Although the diabetic
background did not affect lesion size per se, there was
more intimal calcification in IGF-II/LDLR
-/-ApoB
100/100
mice (18.2 ± 17.3% of plaque area) compared to
hypercholesterolemic LDLR
-/-ApoB
100/100 mice (8.6 ±
6.1% of plaque area) or C57Bl/6J mice (no calcification
detected) (Figure 2B, D). Atherosclerosis was associated
with compensatory enlargement of the vessel area with
a vascular remodeling ratio of 2.63 ± 0.32 in LDLR
-/-
ApoB
100/100 and 2.79 ± 0.28 in IGF-II/LDLR
-/-ApoB
100/
100 mice compared to C57Bl/6J mice (Figure 2C). Con-
sequently, despite extensive atherosclerosis, lumen areas
were not decreased in LDLR
-/-ApoB
100/100 (690.3 ±
201.2 × 10
3 μm
2) or IGF-II/LDLR
-/-ApoB
100/100 mice
(756.4 ± 149.9 × 10
3 μm
2)c o m p a r e dt on o n - a t h e r o -
sclerotic C57Bl/6J controls (716.4 ± 112.9 × 10
3 μm
2).
Severe coronary artery stenosis in hypercholesterolemic
mice
Significant stenosis was observed in ostial parts of cor-
onary arteries in LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-
ApoB
100/100 mice. The stenosis was most prominent in
the left coronary artery, which was narrowed in all stu-
died LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100
mice with average luminal stenosis of 79.4 ± 14.3% and
85.0 ± 6.5%, respectively (Figure 3A, C). This was
accompanied with outward remodeling: compared to
C57Bl/6J, remodeling ratio of the left coronary artery
was 3.17 ± 2.65 in LDLR
-/-ApoB
100/100 and 3.94 ± 2.08
in IGF-II/LDLR
-/-ApoB
100/100 mice (Figure 3B). How-
ever, in spite of the vessel enlargement, significant
decrease of the left coronary artery lumen area was pre-
sent in both LDLR
-/-ApoB
100/100 (8.3 ± 5.8 × 10
3 μm
2, P
< 0.01) and IGF-II/LDLR
-/-ApoB
100/100 mice (9.8 ± 4.9 ×
10
3 μm
2, P < 0.05) compared to C57Bl/6J controls (19.3
± 10.0 × 10
3 μm
2). In the right coronary artery, 22% of
LDLR
-/-ApoB
100/100 and 50% of IGF-II/LDLR
-/-ApoB
100/
100 mice showed mean stenosis of 76.1 ± 8.2% and 86.2
± 7.6%, respectively (Figure 3A). Stenosis of the septal
artery was detected in 50% of mice in both groups with
average stenosis of 92.0 ± 10.0% in LDLR
-/-ApoB
100/100
and 74.7 ± 31.6% in IGF-II/LDLR
-/-ApoB
100/100 mice
(Figure 3A). Despite severe atherosclerosis in the proxi-
mal coronary arteries, no lesions were detected in the
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observed in any part of the coronary tree.
Coronary atherosclerosis leads to left ventricular
dysfunction
Echocardiography was performed to examine in vivo LV
function. LV chamber dimensions, anterior wall (AW)
and posterior wall (PW) thicknesses and LV mass were
obtained from M-mode images (Table 1). Compared to
C57Bl/6J mice, LV end-diastolic and end-systolic dia-
meters were significantly increased in both LDLR
-/-
ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100 mice. LV
dilatation was demonstrated by increased LV end-dia-
stolic and end-systolic volumes and dilatation was most
pronounced in LDLR
-/-ApoB
100/100 mice. Related to LV
dilatation, reduced thickness of both posterior and ante-
rior LV wall was evident in both LDLR
-/-ApoB
100/100
and IGF-II/LDLR
-/-ApoB
100/100 mice. In line with the
impaired cardiac function, resting heart rate was higher
in LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100
mice compared to C57Bl/6J controls.
LV systolic function was evaluated with the Teicholz
method of the EF and FS in M-mode images. Both were
significantly reduced in LDLR
-/-ApoB
100/100 and IGF-II/
LDLR
-/-ApoB
100/100 mice depicting severe contractile
dysfunction, whereas C57Bl/6J controls showed normal
cardiac function (Table 1). In visual evaluation of the
parasternal long axis 2-dimensional EKV™ cine loops
[see Additional files 1, 2 &3], LVAWs of the C57Bl/6J
controls were mostly normokinetic with only mild hypo-
kinesia noted in two animals and a dyskinetic area in
one animal. Impaired wall motion with hypokinesia was
common in LDLR
-/-ApoB
100/100 (in 10/13 mice, 76.9%)
and IGF-II/LDLR
-/-ApoB
100/100 mice (in 8/11 mice,
Table 1 Metabolic parameters, echocardiographic measurements and myocardial perfusion
C57Bl/6J LDLR
-/-ApoB
100/100 IGF-II/LDLR
-/-ApoB
100/100
Metabolic parameters
Body weight (g)
Females 34.4 ± 6.5 28.8 ± 1.9 33.3 ± 3.1
Males 45.8 ± 5.6
‡ 35.4 ± 4.2*
‡ 36.8 ± 3.7
Glucose (mmol/l) 3.5 ± 0.8 5.2 ± 1.0 8.2 ± 3.0*
†
Cholesterol (mmol/l) 3.9 ± 1.4 25.5 ± 7.9* 27.8 ± 5.0*
Triglycerides (mmol/l) 1.0 ± 0.3 1.1 ± 0.3 1.5 ± 0.5*
†
Echocardiographic measurements in baseline
HR (bpm) 443.5 ± 41.0 504.8 ± 14.1* 486.1 ± 30.1*
Dimensions
LVIDED (mm) 3.45 ± 0.38 4.13 ± 0.61* 4.09 ± 0.38*
LVIDES (mm) 2.3 ± 0.44 3.25 ± 0.80* 3.14 ± 0.51*
LVPW;d (mm) 1.26 ± 0.27 0.88 ± 0.18* 0.90 ± 0.18*
LVPW;s (mm) 1.70 ± 0.34 1.13 ± 0.24* 1.15 ± 0.26*
LVAW;d (mm) 1.22 ± 0.17 0.95 ± 0.17* 1.04 ± 0.13*
LVAW;s (mm) 1.77 ± 0.22 1.18 ± 0.25* 1.39 ± 0.22*
LV Vol;d (μl) 49.88 ± 12.34 77.88 ± 26.49* 71.11 ± 12.43*
LV Vol;s (μl) 14.22 ± 7.32 46.23 ± 27.07* 37.59 ± 13.37*
LV Mass/Body weight 4.42 ± 0.69 4.73 ± 1.58 4.10 ± 0.78
Systolic function
EF (%) 72.98 ± 9.45 44.86 ± 14.70* 48.17 ± 11.06*
FS (%) 41.74 ± 7.72 22.46 ± 8.23* 26.83 ± 10.73*
Myocardial perfusion
(ratio to C57Bl/6J)
LVAW 1.00 ± 0.06 0.97 ± 0.09 0.93 ± 0.19
Values denote mean ± SD of 12-15 C57Bl/6J mice, 9-12 LDLR
-/-ApoB
100/100 mice and 10-14 IGF-II/LDLR
-/-ApoB
100/100 mice. Metabolic parameters represent values
after overnight fasting. Glucose was measured from whole blood. Cholesterol and triglycerides were analyzed from plasma. Cardiac measurements were obtained
from echocardiography. Perfusion was measured with contrast pulse sequence ultrasound. HR, heart rate; LV, left ventricle; ID, internal diameter; ED, end-diastole;
ES, end-systole; s, systole; d, diastole; PW, posterior wall; AW, anterior wall; Vol, volume; EF, ejection fraction; FS, fractional shortening.
*P < 0.05 vs. C57Bl/6J
† P < 0.05 vs. LDLR
-/-ApoB
100/100
‡ P < 0.05 vs. females of the same strain
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four animals: one LDLR
-/-ApoB
100/100 and three IGF-II/
LDLR
-/-ApoB
100/100 mice. Animals with severe LV wall
dysfunction had high aortic lesion area (> 70%), calcified
plaques (4 - 12% of plaque area), severe coronary artery
stenosis (> 93% occlusion in left coronary artery) and
LV ejection fraction of 18 - 41%. Despite of the detected
akinesia in the echocardiograms there were neither
increased echogenicity of the affected area, nor histolo-
gical observations of increased fibrosis referring to myo-
cardial infarction scar in Masson-Trichrome stained
serial sections (data not shown). Moreover, although the
overall mortality did not differ between mouse models,
one animal in both LDLR
-/-ApoB
100/100 and IGF-II/
LDLR
-/-ApoB
100/100 groups collapsed and died during
isoflurane anesthesia.
Cardiac reserve is preserved but reduced in
atherosclerotic mice
To examine the myocardial viability, dobutamine stress
echocardiography was performed to evaluate cardiac
reserve. The timepoint of individual peak response after
dobutamine administration varied between 5 and 15
minutes and analyses were performed from the maximal
response values (Table 2). Dobutamine-induced chrono-
tropic responses correlated inversely with baseline heart
rates: C57Bl/6J mice with the lowest resting heart rate
showed the highest increase of 13.2 ± 8.5% (P = 0.043
compared to baseline), whereas in IGF-II/LDLR
-/-
ApoB
100/100 mice the heart rate increased 9.9 ± 4.9% (P
= 0.011) and in LDLR
-/-ApoB
100/100 mice with the
highest resting heart rate the increase was only 6.2 ±
6.5% (P = 0.070).
In parallel, significant enhancement in systolic func-
tion (ΔEF, ΔFS) was seen in all strains and increased
myocardial contractility, depicted by increased thickness
of the LV walls, was as well observed (Table 2 Figure 4).
Furthermore, both diastolic and systolic LV dimensions
decreased significantly. Although rather equal in percen-
tage, the overall response to dobutamine was diminished
in relation to baseline values in both diabetic and non-
diabetic LDLR
-/-ApoB
100/100 mice. However, all mice
responded to the b-adrenergic stimulation and their wall
motion improved (Figure 4). Due to a limited sample
size (n = 5-6/strain), change in the wall motion score
index was statistically significant only in LDLR
-/-
ApoB
100/100 mice (P < 0.001). This was possibly influ-
enced also by their significantly poorer baseline score
(1.70 ± 0.12) compared to IGF-II/LDLR
-/-ApoB
100/100
(1.26 ± 0.17, P < 0.01) and C57Bl/6J mice (1.14 ± 0.20,
P < 0.001).
Myocardial perfusion correlates with the atherosclerotic
burden
Measured with contrast pulse sequence ultrasound,
there were no statistically significant differences in
LVAW perfusion between the groups (Table 1). How-
ever, a trend towards decreased myocardial perfusion
w a ss e e ni nL D L R
-/-ApoB
100/100 and IGF-II/LDLR
-/-
ApoB
100/100 mice.
Ultrastructural analysis of myocardium reveals
degenerative changes in hypercholesterolemic mice
In electron microscopy analysis ventricular myocardium
showed degenerative changes (Figure 5). Cardiomyocytes
with impaired cytoarchitecture, autophagosomes,
decreased number of myofibrils and increased interfi-
brillar space with collagen fibrils, irregularly shaped
dense bodies, myelin figures and focal deposits of glyco-
gen were observed. Mitochondria were polymorphic and
often doughnut-like. The changes were present in both
LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100
mice.
Discussion
In the present study the effects of type 2 diabetes on
coronary artery disease and cardiac function were inves-
tigated in 18-month-old mice after three months of
Western diet. We found notable stenosis in proximal
coronary arteries in both LDLR
-/-ApoB
100/100 and dia-
betic IGF-II/LDLR
-/-ApoB
100/100 mice and the stenoses
were most severe in the left coronary artery, which was
significantly narrowed in all animals of these groups
despite compensatory vessel remodeling. Since type 2
diabetes increases significantly the risk of coronary
Figure 1 IGF-II/LDLR
-/-ApoB
100/100 mice show elevated fasting
glucose and glucose intolerance in an intraperitoneal GTT.
Values denote mean ± SD of 9 (LDLR
-/-ApoB
100/100) or 12 (C57Bl/6J
and IGF-II/LDLR
-/-ApoB
100/100) 18-month-old mice. * P < 0.05 in IGF-
II/LDLR
-/-ApoB
100/100 versus C57Bl/6J and LDLR
-/-ApoB
100/100 mice, †
P < 0.05 between IGF-II/LDLR
-/-ApoB
100/100 and LDLR
-/-ApoB
100/100
mice, ‡ P < 0.05 between IGF-II/LDLR
-/-ApoB
100/100 and C57Bl/6J
mice.
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would be worse in the diabetic animals. Regardless of
increased intimal calcification in aortic lesions of the
IGF-II/LDLR
-/-ApoB
100/100 mice, diabetes did not lead
to a worsened CAD compared to hypercholesterolemic
LDLR
-/-ApoB
100/100 mice. Also LV function was equally
impaired in both hypercholesterolemic mouse strains
compared to age- and diet-matched C57Bl/6J mice.
Based on these findings the impaired cardiac function in
IGF-II/LDLR
-/-ApoB
100/100 mice does not seem to be
related to diabetes. This is likely subsequent to the high
plasma cholesterol levels of the LDLR
-/-ApoB
100/100
background in both models, since it is widely recognized
that cholesterol is the main driving force behind athero-
genesis in mice. However, because the cholesterol levels
in our study were equal in diabetic and non-diabetic
LDLR
-/-ApoB
100/100 mice, detecting the effects of dia-
betes is possible, whereas the diabetes-induced elevation
in plasma lipids seen in most models of diabetic athero-
sclerosis hampers dissecting the contribution of other
metabolic factors on cardiovascular outcome [15].
Although genetically-modified mouse models of
hypercholesterolemia are widely used in cardiovascular
research [26,27], the status of coronary arteries and
potential manifestation of myocardial infarction have
been studied to a lesser extent. In the commonly used
LDLR
-/- mice CAD seems to be absent even if athero-
genic diet is used [28]. Lesions in coronary arteries and
myocardial fibrosis were described in Western diet fed
ApoE
-/- mice shortly after the model was generated [29],
but since then controversial results have been reported:
coronary artery occlusion and subsequent evidence of
apical infarction are found by some [30], whereas in
other studies the coronary arteries are found to be
totally clean [31] or lesions are seen only in proximal
parts of the arteries without signs of infracted
Figure 2 Evaluation of aortic atherosclerosis and vascular remodeling. A) Cross-sectional lesion areas from the aortic sinus level, B)
calcification of atherosclerotic plaques and C) average absolute vessel (white bars) and lesion areas (black bars) in the aortic sinus (mean ± SD)
of 18-month-old mice. In comparison to C57Bl/6J controls (n = 8), compensatory enlargement of vessel area is seen in LDLR
-/-ApoB
100/100 (n = 9)
and IGF-II/LDLR
-/-ApoB
100/100 mice (n = 11) with vascular remodeling ratios in parenthesis indicating positive remodeling (> 1.05) in response to
atherosclerosis. * P < 0.05 versus C57Bl/6J. D) Representative hematoxylin-eosin stained aortic sections from sinus level of C57Bl/6J (left panel),
LDLR
-/-ApoB
100/100 (middle) and IGF-II/LDLR
-/-ApoB
100/100 mice (right panel). Original magnification × 40, scale bar 100 μm.
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absolute vessel (white bars) and respective lesion areas (black bars) in the left coronary artery of 18-month-old mice (mean ± SD). In comparison
to C57Bl/6J controls (n = 9), compensatory enlargement of the left coronary artery is seen in LDLR
-/-ApoB
100/100 (n = 7) and IGF-II/LDLR
-/-
ApoB
100/100 mice (n = 7) with vascular remodeling ratios in parenthesis indicating positive remodeling (> 1.05) in response to atherosclerosis. * P
< 0.05 versus C57Bl/6J. C) Representative hematoxylin-eosin stained sections showing severe stenosis in proximal left coronary artery in LDLR
-/-
ApoB
100/100 (middle) and IGF-II/LDLR
-/-ApoB
100/100 mice (right panel). Original magnification × 200, scale bar 25 μm.
Table 2 Dobutamine stress induced changes in echocardiographic parameters
% C57Bl/6J LDLR
-/-ApoB
100/100 IGF-II/LDLR
-/-ApoB
100/100
ΔHR 13.22 ± 8.45 (0.043) 6.19 ± 6.52 (0.070) 9.86 ± 4.93 (0.011)
ΔEF 14.87 ± 4.51 (0.001) 16.83 ± 1.52 (< 0.0001) 16.79 ± 8.53 (0.001)
ΔFS 15.48 ± 6.00 (0.005) 11.91 ± 2.18 (0.003) 13.74 ± 7.44 (0.0145)
ΔLVIDED -9.4 ± 4.5 (0.009) -12.7 ± 6.7 (0.016) -9.3 ± 3.7 (0.032)
ΔLVIDES -31.9 ± 11.1 (0.002) -24.6 ± 6.8 (0.001) -24.9 ± 13.0 (0.017)
ΔLVPW;d 18.0 ± 2.9 (0.099) 19.6 ± 8.4 (0.006) 18.5 ± 11.3 (0.021)
ΔLVPW;s 37.4 ± 19.1 (0.184) 29.7 ± 7.9 (0.0004) 28.3 ± 13.9 (0.004)
ΔLVAW;d 26.7 ± 22.0 (0.863) 23.0 ± 25.7 (0.078) 28.0 ± 12.0 (0.005)
ΔLVAW;s 32.3 ± 10.9 (0.001) 26.6 ± 15.6 (0.010) 28.0 ± 16.6 (0.004)
ΔLV Vol;d -20.5 ± 9.6 (0.009) -25.5 ± 14.1 (0.012) -20.7 ± 7.6 (0.006)
ΔLV Vol;s -61.1 ± 16.8 (0.002) -50.0 ± 12.0 (0.002) -51.6 ± 19.2 (0.012)
Values denote mean ± SD. Dobutamine challenge was performed to 5 (LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100) or 6 mice (C57Bl/6J) per
strain. P-values from paired t-test comparing group baseline and the maximal response after dobutamine are shown in parenthesis.
Heinonen et al. Cardiovascular Diabetology 2011, 10:59
http://www.cardiab.com/content/10/1/59
Page 7 of 12myocardium [31-33]. The latter has been found also in
the LDLR
-/-ApoB
100/100 mice by Saraste et al. [34] and
verified in the present study. In the severely hypercho-
lesterolemic ApoE
-/-LDLR
-/- mice both distal coronary
artery lesions and myocardial infarction have been
reported [35,36]. The gravest phenotype is in double
knockout mice lacking scavenger receptor class B type I
(SR-BI) and ApoE - the mice die of CAD induced myo-
cardial infarction by 8 weeks of age [37].
Positive or outward arterial remodeling is a compensa-
tory increase in vessel size in order to maintain luminal
area in atherosclerosis [38]. Whereas clinical studies on
vascular remodeling in different disease states are
abundant, less is known about it in experimental mod-
els, especially mice. Positive remodeling has been
observed in aortic sinus [39] as well as in carotid, thor-
acic and abdominal aortas of ApoE
-/- mice [24,40]. Con-
sistent with this data, our results show enlargement of
vessel areas in both aortic sinus and coronary arteries.
In aortic sinus this compensatory remodeling resulted in
maintenance of a lumen area equal to non-atherosclero-
tic C57Bl/6J controls, whereas in left coronary artery the
lumen was significantly narrowed. Since stenosis was
g r e a t e ri nc o r o n a r ya r t e r i e s( ~ 8 0 % )t h a ni nt h ea o r t i c
sinus (~60%), this might reflect a similar observation
made in humans: once certain threshold in plaque
deposition is exceeded, further enlargement might not
be possible and lumen area is compromised by the
growing lesion [38]. To our knowledge, vascular remo-
deling has been previously studied neither in mouse cor-
onary arteries nor in a model of diabetic atherosclerosis.
Because of the increased risk for cardiac events in dia-
betes, this is a matter of interest. Association between
positive remodeling and unstable lesions has been
Figure 4 Dobutamine stress echocardiography.M - m o d es h o r t -
axis views of the left mid-ventricle before and after b-adrenergic
stimulation with dobutamine in an 18-month-old A) C57Bl/6J, B)
IGF-II/LDLR
-/-ApoB
100/100 and C) LDLR
-/-ApoB
100/100 mouse.
Compared to the C57Bl/6J control, IGF-II/LDLR
-/-ApoB
100/100 and
LDLR
-/-ApoB
100/100 mice show reduced contractility. D) Regional wall
motion analysis represents improvement of systolic function after
dobutamine in all mouse strains, although statistically significant
only in LDLR
-/-ApoB
100/100 mice. Results are mean ± SD of 5 (LDLR
-/-
ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100) or 6 animals (C57Bl/6J).
Figure 5 Representative images of ultrastructural changes
found in LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100 mice.
A) On the left, impaired cytoarchitecture with increased interfibrillar
space, dense bodies (db) and polymorphic and often doughnut-like
mitochondria (am, abnormal mitochondria). Note autophagosome
(a) in the preserved area. Nm, normal mitochondria; m, myofiber. B)
Detail of the damaged area with increased number of enlarged
abnormal mitochondria (am), lysosomes (l) and sparse glycogen
deposits (g). C) Increased interfibrillar space filled with
autophagosomes (a), dense bodies (db), collagen fibrils (cf) and
glycogen deposits (g). D) Detail on myelin figures (mf) and
glycogen deposits (g). Images are from IGF-II/LDLR
-/-ApoB
100/100
mice. Bars 1.0 μm (A, B), 0.2 μm (C) and 0.5 μm (D).
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that outward remodeling would be greater in diabetic
patients with accelerated atherosclerosis and thus possi-
bly also in the diabetic IGF-II/LDLR
-/-ApoB
100/100 mice
with a more inflammatory vascular phenotype and
advanced lesions [20]. On the other hand, also negative
remodeling could contribute to the increased incidence
of cardiac events in diabetics. However, in the present
study diabetes did not lead to either of these but the
remodeling was equal compared to non-diabetic mice
with similar atherosclerosis. Inconsistent findings have
been done also in humans: both increased [43] and
inadequate compensatory remodeling [44] have been
detected with intravascular ultrasound, calling for more
in-depth studies in experimental models.
Atherosclerosis as a progressive disease and aging is
associated with general cardiovascular changes [45].
Compared to our former characterization of 15-month-
old animals [20], older age of mice in the present study
reflected as an analogous augmentation of atherosclerotic
calcification in both diabetic and non-diabetic LDLR
-/-
ApoB
100/100 mice. Also plasma triglyceride levels of the
IGF-II/LDLR
-/-ApoB
100/100 mice were now higher than in
LDLR
-/-ApoB
100/100 mice and could in theory contribute
to increased calcification. However, this is unlikely, since
the level was still in the normal range and numerically
only marginally higher than in the LDLR
-/-ApoB
100/100
mice. In addition, in our previous study the situation was
vice versa and yet there was more calcification in the
IGF-II/LDLR
-/-ApoB
100/100 m i c e .T h u st h ed i f f e r e n c ei n
plasma triglycerides most probably describes natural fluc-
tuation. Moreover, no significant correlation between
lipid levels and level of calcification were noted. There-
fore the physiological significance of minor changes in
triglycerides is unlikely, especially in the presence of
severe hypercholesterolemia.
Despite prominent stenosis in proximal coronary
arteries and observed regional akinesia in LVAW of
LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-ApoB
100/100
mice, signs of myocardial infarction were not found.
Thus, the observed severe LV dysfunction most likely
results from adaptation to chronic hypoperfusion rather
than acute ischemic events. In support of this the rest-
ing perfusion in LVAW was only slightly reduced, which
is in line with the study observing reduced coronary
flow reserve in old, Western diet fed LDLR
-/-ApoB
100/100
mice [34]. Cardiac functional reserve after dobutamine
challenge was preserved, although depressed compared
to C57Bl/6 controls, indicating that the dysfunctional
myocardium of LDLR
-/-ApoB
100/100 and IGF-II/LDLR
-/-
ApoB
100/100 mice was not scarred but viable. Dobuta-
mine stress echocardiography is a feasible non-invasive
method to gain information about cardiac function and
capacity, and to predict reversibility of wall motion after
revascularization [46]. In ApoE
-/- mice the cardiac func-
tional reserve has been found to be reduced [47]. Also
in diabetic db/db [48] and ob/ob mice [18] the response
to b-adrenergic stimulation has been shown to be
decreased. So far the only study done in a mouse model
of diabetic atherosclerosis showed impaired cardiac
reserve in the ob/ob/LDLR
-/- mice [18].
In patients with ischemic cardiomyopathy, hibernating
myocardium is an important clinical entity with signifi-
cant prognostic value when considering revasculariza-
tion procedures. Myocardial hibernation is referred as a
state of reduced contractile function in the setting of
CAD that is reversible with revascularization. Interest-
ingly, various results in the present study suggest myo-
cardial hibernation: LV dysfunction distal to coronary
stenosis, preserved inotropic reserve, absence of necrosis
and minor reduction in myocardial perfusion. Also the
ultrastructural findings in LDLR
-/-ApoB
100/100 and IGF-
II/LDLR
-/-ApoB
100/100 mice support the possibility of
hibernation, since the morphological hallmarks of
chronic myocardial hibernation include signs of atrophy
(especially contractile myofibrils and loss of cardiomyo-
cytes) and degenerative changes (disorganization of
cytoskeleton, cellular debris in interstitium, increased
collagen and glycogen) without necrosis [49]. As a lim-
itation to the hypothesis of myocardial hibernation,
some of the changes seen in LDLR
-/-ApoB
100/100 and
IGF-II/LDLR
-/-ApoB
100/100 mice could be induced also
by aging. However, there is a general lack of suitable
animal models that has hampered the studies of myo-
cardial hibernation. Because achieving reproducible and
chronic partial coronary artery stenosis without infarc-
tion is technically very challenging, most experimental
studies of myocardial hibernation have been done in lar-
g e ra n i m a l s ,s u c ha sd o g sa n dp i g s[ 4 9 , 5 0 ] .T h ef e w
mouse models reported are mainly based a short-term
hypoperfusion [51] or genetic manipulation of e.g. myo-
cardial angiogenesis [52]. Since chronic CAD and the
resulting gradual intravascular occlusion are the major
causes of ischemic cardiomyopathy in humans, it would
be aspired to have them manifested also in the experi-
mental animal model. Even if the model would not per-
fectly reproduce the human condition and the actual
revascularization procedures as an affirmation of the
hibernation are not technically feasible in mice, animal
models can provide unique and valuable information.
Conclusions
Hypercholesterolemic LDLR
-/-ApoB
100/100 mice with or
without type 2 diabetes develop significant coronary
artery atherosclerosis with positive arterial remodeling,
severe left ventricular dysfunction with regional akinesia
distal to coronary stenosis without signs of infarction,
and represent preserved but reduced cardiac functional
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Page 9 of 12reserve and histological features referring to chronic
myocardial hibernation. Hence, the cardiac outcome was
not worsened by type 2 diabetes, probably because of
dominant effect of severe hypercholesterolemia caused
by the LDLR
-/-ApoB
100/100 background. Since animal
models describing type 2 diabetic macrovascular diseases
are few, a thorough characterization of the vascular and
cardiac phenotype of a mouse model combining com-
mon metabolic disorders, CAD and chronic myocardial
hypoperfusion provides valuable information and offers
a tool for experimental and translational research.
Additional material
Additional file 1: Long axis EKV™™ cine loop of a C57Bl/6J mouse.
Transthoracic echocardiography in C57Bl/6J mouse was performed with
Vevo 770 high-resolution imaging system. Long axis cine loops showed
preserved normal function of the left ventricular walls. No atherosclerotic
lesion development was seen in either aorta or coronary arteries. Ejection
fraction was 79.9%.
Additional file 2: Long axis EKV™™ cine loop of a LDLR
-/-ApoB
100/
100 mouse. Transthoracic echocardiography was performed with Vevo
770 high-resolution imaging system. Long axis electrocardiogram
kilohertz-based visualization (EKV™™) cine loops show a poor systolic
function (ejection fraction 18.1%) in a LDLR
-/-ApoB
100/100 mouse. The left
ventricle was dilated with anteroapical akinesia and hypokinetic posterior
wall. The mouse had aortic cross-sectional lesion area of 73.3% with
calcification and the left coronary artery was markedly stenosed (94.3%).
Additional file 3: Long axis EKV™™ cine loop of an IGF-II/LDLR
-/-
ApoB
100/100 mouse. Transthoracic echocardiography was performed
with Vevo 770 high-resolution imaging system. Long axis cine loops
showed markedly reduced anteroapical wall motion in the left ventricle
in an IGF-II/LDLR
-/-ApoB
100/100 mouse, which presented calcified lesions
covering 70% of the aortic lumen area at the sinus level and significant
stenosis in both left and right coronary arteries (99.5% and 93.2%,
respectively). Ejection fraction was reduced (41.2%) compared to control
C57Bl/6 mice.
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